Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the dosing of the first subject in...
AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease
AbbVie Inc. (NYSE: ABBV) has announced that China’s National Medical Products Administration (NMPA) has approved...
IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers
IASO Biotherapeutics, a Chinese cell therapy innovator, has entered into a strategic technology collaboration and...
CanSino Biologics Secures NMPA Approval for Pankangxin, China’s First Three-Component Acellular DTaP Vaccine
CanSino Biologics Inc. (HKG: 6185) has announced that China’s National Medical Products Administration (NMPA) has...
Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value
Zhejiang Medicine Co., Ltd. (SHA: 600216) has announced its strategic intention to spin off its...
Cutia Therapeutics’ CU-20101 Meets Phase III Endpoints, Demonstrating Non-Inferiority to BOTOX for Glabellar Lines
Cutia Therapeutics (HKG: 2487) has announced the successful completion of its pivotal Phase III clinical...
Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle
Hotgen Biotech Co., Ltd. (SHA: 688068) has announced that the National Medical Products Administration (NMPA)...
Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) has entered into a strategic exclusive licensing agreement...
FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), the Australian partner of Grand Pharmaceutical Group Co.,...
GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials
GlaxoSmithKline plc (GSK, NYSE: GSK) has reported highly promising data from the global Phase I...
Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio
Merck KGaA (ETR: MRK) has officially closed its acquisition of the chromatography business from JSR...
Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC
Boehringer Ingelheim and BioNTech SE (NASDAQ: BNTX) have announced a clinical collaboration to evaluate a...
Gaush Meditech Secures CE Mark for Corneal Confocal Microscope, Paving Way for EU Commercial Launch
Gaush Meditech Ltd. (HKG: 2407), a Chinese innovator in ophthalmic medical devices, has announced it...
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced a definitive agreement to acquire fellow U.S. biopharmaceutical...
Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
Nanjing Pharmaceutical Group Co., Ltd. (SHA: 600713) has unveiled a strategic plan to establish a...
Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology
Telix Pharmaceuticals Ltd. (ASX: TLX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced a strategic...
Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio
Sun Pharmaceutical Industries Ltd. (NSE: SUNPHARMA) is in advanced negotiations to acquire Organon & Co....
Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer
Duality Biologics (HKG: 9606), a US‑China dual‑headquartered antibody‑drug conjugate (ADC) developer, announced that the National Medical...
Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer
Oricell Therapeutics Co., Ltd. announced completion of a US$110 million+ pre‑IPO financing round, positioning the cell...
Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease
Sino Biopharmaceutical Ltd (HKG: 1177) announced first patient enrollment in the Phase II Kylo-11-II-C01 study evaluating...